Given the toxicity profile of anti-CTLA-4 and the duration of therapy investigated, adjuvant therapy with either anti-PD-1 agents or dabrafenib–trametinib for patients with BRAF-mutated melanoma is preferred. The gene discussed is CTLA4; the disease is melanoma.